Literature DB >> 19486964

The effect of premenstrual symptoms on activities of daily life.

Lorraine Dennerstein1, Philippe Lehert, Torbjörn Carl Bäckström, Klaas Heinemann.   

Abstract

OBJECTIVE: To assess impact of premenstrual symptoms on activities of women's daily lives (ADL).
DESIGN: Cross-sectional population-based survey.
SETTING: Market research company. PATIENT(S): A total of 4,085 women aged 14-50 years recruited by random telephone digit dialing in France, Germany, Hungary, Italy, Spain, the United Kingdom, Brazil, and Mexico. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): A telephone interview checklist of 23 premenstrual symptoms, sociodemographic and lifestyle variables, and ADL effects (global question and seven areas). Stepwise regression measured the effect of premenstrual symptoms and sociodemographic factors on ADL. RESULT(S): Symptoms and symptom domains (physical and mental) had similar negative effects on ADL. Activities of daily life were predominantly affected by symptom severity. Income level, age, and country also significantly affected ADL. In all, 2,638 women (64.6%) were minimally affected in ADL, 981 (24%) were moderately affected, and 454 (11.1%) were severely affected. CONCLUSION(S): Both physical and mental premenstrual symptoms have significant impact on quality of life, assessed as ADL. Up to 35% of women of reproductive age in Europe and Latin America were moderately or severely affected in ADL by cyclical premenstrual symptoms. Copyright (c) 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19486964     DOI: 10.1016/j.fertnstert.2009.04.023

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  8 in total

1.  Health related quality of life among adolescents with premenstrual disorders: a cross sectional study.

Authors:  Mahin Delara; Fazlollah Ghofranipour; Parviz Azadfallah; Sedigheh Sadat Tavafian; Anoushirvan Kazemnejad; Ali Montazeri
Journal:  Health Qual Life Outcomes       Date:  2012-01-01       Impact factor: 3.186

2.  ISPMD consensus on the management of premenstrual disorders.

Authors:  Tracy Nevatte; Patrick Michael Shaughn O'Brien; Torbjorn Bäckström; Candace Brown; Lorraine Dennerstein; Jean Endicott; C Neill Epperson; Elias Eriksson; Ellen W Freeman; Uriel Halbreich; Khalid Ismail; Nicholas Panay; Teri Pearlstein; Andrea Rapkin; Robert Reid; David Rubinow; Peter Schmidt; Meir Steiner; John Studd; Inger Sundström-Poromaa; Kimberly Yonkers
Journal:  Arch Womens Ment Health       Date:  2013-04-27       Impact factor: 3.633

3.  Premenstrual Syndrome Is Associated with Dietary and Lifestyle Behaviors among University Students: A Cross-Sectional Study from Sharjah, UAE.

Authors:  Mona S Hashim; Asma A Obaideen; Haitham A Jahrami; Hadia Radwan; Hani J Hamad; Alaa A Owais; Lubna G Alardah; Samir Qiblawi; Nabeel Al-Yateem; Mo'ez Al-Islam E Faris
Journal:  Nutrients       Date:  2019-08-17       Impact factor: 5.717

4.  Validation of the Brazilian Portuguese version of the Premenstrual Symptoms Screening Tool (PSST) and association of PSST scores with health-related quality of life.

Authors:  Rachel de A Câmara; Cristiano A Köhler; Benicio N Frey; Thomas N Hyphantis; André F Carvalho
Journal:  Braz J Psychiatry       Date:  2016-11-24       Impact factor: 2.697

5.  Saffron for the Management of Premenstrual Dysphoric Disorder: A Randomized Controlled Trial.

Authors:  Fatemeh Rajabi; Marjan Rahimi; Mohammad Reza Sharbafchizadeh; Mohammad Javad Tarrahi
Journal:  Adv Biomed Res       Date:  2020-10-30

6.  Internet-based cognitive-behavioral therapy for premenstrual syndrome: a randomized controlled trial.

Authors:  Sanam Borji-Navan; Sakineh Mohammad-Alizadeh-Charandabi; Khalil Esmaeilpour; Mojgan Mirghafourvand; Ali Ahmadian-Khooinarood
Journal:  BMC Womens Health       Date:  2022-01-08       Impact factor: 2.809

7.  Premenstrual symptoms across the lifespan in an international sample: data from a mobile application.

Authors:  Liisa Hantsoo; Shivani Rangaswamy; Kristin Voegtline; Rodion Salimgaraev; Liudmila Zhaunova; Jennifer L Payne
Journal:  Arch Womens Ment Health       Date:  2022-08-26       Impact factor: 4.405

8.  Fluoxetine elevates allopregnanolone in female rat brain but inhibits a steroid microsomal dehydrogenase rather than activating an aldo-keto reductase.

Authors:  J P Fry; K Y Li; A J Devall; S Cockcroft; J W Honour; T A Lovick
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.